Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

Summary

NephroNet proposes to examine whether combining Spironolactone with maximal RAAS blockade will further reduce urinary protein at one year and whether prolonged therapy (24 months) is able to slow the decline in GFR. Because of combination MRA and RAAS therapy significantly increases the risk for clinically significant hyperkalemia, we also plan to determine whether the addition of Patiromer to these patients facilitates the use of combination therapy and allows a larger proportion of diabetic patients the potential benefit of combination therapy on renal function.

Timeline

Start

2018-10-01

Primary completion

2022-10-01

Completion

2024-10-01

Drugs

Indications